# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Robert Peary (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-EX004-SYN
- Date: 2026-02-17
- Fictional facility: St. Posthumous Health Center
- Fictional author: Thaddeus Lindgren-Okafor, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Five-week review on the day of upper endoscopy and colonoscopy. **S**

## History of present illness

Admiral Peary is seen in the afternoon after his upper endoscopy and colonoscopy this morning. He has more energy, climbs a flight of stairs without stopping, and walks half a mile with his stick. The pins and needles in his feet are less, though the numbness at the ends of his feet remains. He has given himself three weekly injections without trouble. The blister on his left forefoot healed within two weeks; podiatry saw him twelve days ago, pared the callus and fitted extra-depth shoes with toe fillers. He started physical therapy three weeks ago. He has not fallen. The endoscopist reported pale, thin mucosa in the body of the stomach and a normal antrum, and no polyps in the colon; biopsies are pending. **S**

| Element | Detail |
|---|---|
| Energy | Better; one flight of stairs without stopping |
| Feet | Less tingling; numbness at the ends persists; blister healed |
| Hemoglobin | 12.0 g/dL; MCV 101 fL |
| Potassium | 4.3 mmol/L |
| Endoscopy | Atrophic-looking body mucosa; antrum normal; biopsies pending |
| Colonoscopy | No polyps |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Energy much better |
| Respiratory | Negative | No breathlessness on one flight of stairs |
| Gastrointestinal | Negative | No pain after the procedures |
| Neurological | Positive | Less tingling; numbness at the ends of the feet; no falls |

4 systems reviewed. **S**

## Current medications

- Cyanocobalamin (vitamin B12) 1,000 micrograms (1 mg/mL) intramuscular injection once a week while the nerves recover **S**

## Allergies

- No known allergy **S**

## Objective

BP 126/72 mmHg; pulse 80 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 73.4 kg; BMI 21.9 kg/m². All vital signs are synthetic.

Hemoglobin: 12 g/dL (low); MCV: 101 fL (high); White blood cells: 5.6 10*3/uL; Platelets: 232 10*3/uL; Reticulocytes: 1.6%; Potassium: 4.3 mmol/L. All results are synthetic.

## Change since baseline

- Hemoglobin: 8.2 g/dL (low) at baseline, 12 g/dL (low) at this visit **S**
- MCV: 118 fL (high) at baseline, 101 fL (high) at this visit **S**
- White blood cells: 3.4 10*3/uL (low) at baseline, 5.6 10*3/uL at this visit **S**
- Platelets: 118 10*3/uL (low) at baseline, 232 10*3/uL at this visit **S**
- Reticulocytes: 0.4% (low) at baseline, 1.6% at this visit **S**
- Potassium: 4.1 mmol/L at baseline, 4.3 mmol/L at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Better color; blood pressure 126/72, pulse 80 |
| Neurological | Vibration absent at the ankles, present at the knees; joint position sense now normal at the great toes; ankle jerks absent; Romberg sway without falling; Timed Up and Go 12 seconds |
| Feet | Left forefoot blister site healed; callus pared; skin intact |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Pernicious anemia on weekly cyanocobalamin** (D51.0). Hemoglobin up from 8.2 to 12.0 g/dL with MCV falling from 118 to 101 fL at five weeks; potassium normal. **S**
   - Continue weekly injections.
   - Eight-week review with the blood count, methylmalonic acid, homocysteine and iron studies, and the biopsy results.
2. **Subacute combined degeneration** (G32.0). Early recovery of joint position sense and balance. **S**
   - Continue physical therapy and the home balance exercises.
3. **Blister on the left forefoot** (S90.822A). Healed. **S**
   - Extra-depth shoes with toe fillers; daily checks.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Symptoms: fatigue, breathlessness, exercise tolerance, sore tongue, numbness | Every visit during active treatment | Completed today | Energy and breathing better; tingling less |
| Laboratory | Blood count with MCV | About eight weeks after starting replacement, with earlier checks in severe anemia | Completed today | Hemoglobin 12.0 g/dL, MCV 101 fL, white cells 5.6, platelets 232; full check due at eight weeks |
| Laboratory | Reticulocyte count | About one week after the first injection | Completed today | 1.6%, settling after the peak |
| Laboratory | Potassium | In the first days of treatment of severe anemia | Completed today | 4.3 mmol/L, the check planned after the missed early potassium |
| Laboratory | Methylmalonic acid and homocysteine | One week to three months after starting replacement | Due | At the eight-week review |
| Medication safety | Injection plan: doses given, self-injection technique, site problems | Every visit | Completed today | Seven loading doses and three weekly self-injections given; technique good |
| Examination | Neurological examination: vibration, joint position, reflexes, Romberg, gait, cognition | At diagnosis and at follow-up visits for six weeks to three months, then until recovery levels off | Completed today | Joint position sense recovered at the great toes; vibration still absent at the ankles; Romberg sway |
| Examination | Falls and gait: falls since the last visit, Timed Up and Go, home hazards | Every visit | Completed today | No falls; Timed Up and Go 12 seconds, from 14 |
| Examination | Upper endoscopy with Sydney-protocol biopsies for autoimmune gastritis, neuroendocrine tumors and dysplasia | At diagnosis of pernicious anemia; then by individual risk | Completed today | Done this morning with Sydney-protocol biopsies; body mucosa pale and thin, antrum normal, no polyp or mass; colonoscopy without polyps |
| Self-management | Feet: daily skin checks, footwear, callus and stump skin, monofilament | Every visit | Completed today | Blister healed; daily checks kept; new extra-depth shoes |
| Referral | Podiatry | Within four weeks of intake, then every three months | Completed today | Seen twelve days ago, three weeks after intake, after the blister; callus pared and shoes fitted; next visit in three months |
| Referral | Physical therapy for balance and gait | From diagnosis until balance recovers | Completed today | Started three weeks ago, twice a week |

## Goal progress

- Find the cause of the anemia and the numb feet. Outcome by 2026-01-21: Pernicious anemia confirmed: intrinsic factor and parietal cell antibodies positive, gastrin high. **S**
- Normal hemoglobin and MCV within eight weeks. In progress; target 2026-03-10. **S**
- Recover feeling and balance in the feet and walk without falls. In progress; target 2026-10-27. **S**
- No foot wound that goes unnoticed. In progress; target 2026-10-27. **S**
- Gastric surveillance planned with him. In progress; target 2026-03-10. **S**

## Guideline basis

- Guidelines for the diagnosis and treatment of cobalamin and folate disorders (2014), British Committee for Standards in Haematology (British Journal of Haematology 2014;166(4):496-513)
- Vitamin B12 deficiency in over 16s: diagnosis and management (NG239) (2024), National Institute for Health and Care Excellence
- AGA Clinical Practice Update on the Diagnosis and Management of Atrophic Gastritis: Expert Review (2021), American Gastroenterological Association (Gastroenterology 2021;161(4):1325-1332)
- CMID: Clinical Monitoring Intelligence Database, anemia and depression, bipolar, and mood disorders monographs (2026), Aether Forge
- Guidelines on the prevention of foot ulcers in persons with diabetes (IWGDF 2023 update) (2023), International Working Group on the Diabetic Foot (Diabetes/Metabolism Research and Reviews 2024;40(3):e3651)
- Falls Prevention in Community-Dwelling Older Adults: Interventions (2024), U.S. Preventive Services Task Force
- Colorectal Cancer: Screening (2021), U.S. Preventive Services Task Force

## Follow-up

- Eight-week review in three weeks with the blood tests and the biopsy results. Continue weekly injections. **S**
- Next scheduled visit 2026-03-10: eight-week review: blood count, methylmalonic acid, iron studies, the endoscopy biopsies and surveillance. **S**
